Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results
Interpace Biosciences (OTCQX:IDXG) reported mixed Q2 2025 financial results, with net revenue of $9.2 million, down 23% year-over-year. Despite overall revenue decline, the company achieved record thyroid testing performance, with volume up 16% and revenue up 25% year-over-year to $8.7 million.
The company reported a Q2 loss from continuing operations of $0.5 million, compared to income of $2.5 million in Q2 2024, primarily impacted by $1.2 million in one-time charges related to PancraGEN testing discontinuation. Cash collections remained strong at $10.8 million, and preliminary July 2025 revenue showed a 54% year-over-year increase to $3.3 million.
Interpace is transitioning to focus exclusively on thyroid testing, following the loss of PancraGEN reimbursement. The company maintains a positive outlook for Q3 2025 and beyond as a thyroid-only diagnostics business.
Interpace Biosciences (OTCQX:IDXG) ha riportato risultati finanziari misti per il secondo trimestre del 2025, con un ricavo netto di 9,2 milioni di dollari, in calo del 23% rispetto all'anno precedente. Nonostante la diminuzione complessiva dei ricavi, l'azienda ha raggiunto una performance record nei test per la tiroide, con un aumento del volume del 16% e dei ricavi del 25% anno su anno, pari a 8,7 milioni di dollari.
L'azienda ha registrato una perdita di 0,5 milioni di dollari dalle operazioni continue nel secondo trimestre, rispetto a un utile di 2,5 milioni nel Q2 2024, principalmente a causa di oneri una tantum di 1,2 milioni legati alla cessazione dei test PancraGEN. Le riscossioni in contanti sono rimaste solide a 10,8 milioni di dollari, mentre i ricavi preliminari di luglio 2025 hanno mostrato un aumento del 54% su base annua, raggiungendo 3,3 milioni di dollari.
Interpace sta effettuando una transizione per concentrarsi esclusivamente sui test per la tiroide, a seguito della perdita del rimborso per PancraGEN. L'azienda mantiene una prospettiva positiva per il terzo trimestre 2025 e oltre, come impresa diagnostica focalizzata solo sulla tiroide.
Interpace Biosciences (OTCQX:IDXG) reportó resultados financieros mixtos en el segundo trimestre de 2025, con un ingreso neto de 9,2 millones de dólares, una disminución del 23% interanual. A pesar de la caída general en los ingresos, la compañía logró un récord en el desempeño de pruebas de tiroides, con un aumento del 16% en volumen y un incremento del 25% en ingresos interanuales, alcanzando los 8,7 millones de dólares.
La empresa reportó una pérdida de 0,5 millones de dólares en operaciones continuas en el segundo trimestre, en comparación con una ganancia de 2,5 millones en el Q2 de 2024, afectada principalmente por cargos únicos de 1,2 millones relacionados con la descontinuación de las pruebas PancraGEN. Las cobranzas en efectivo se mantuvieron sólidas en 10,8 millones de dólares, y los ingresos preliminares de julio de 2025 mostraron un aumento interanual del 54%, alcanzando 3,3 millones de dólares.
Interpace está en proceso de transición para enfocarse exclusivamente en pruebas de tiroides, tras la pérdida del reembolso de PancraGEN. La compañía mantiene una perspectiva positiva para el tercer trimestre de 2025 y más allá como un negocio diagnóstico exclusivo de tiroides.
Interpace Biosciences (OTCQX:IDXG)는 2025년 2분기 실적에서 혼합된 결과를 보고했으며, 순매출 920만 달러로 전년 동기 대비 23% 감소했습니다. 전체 매출 감소에도 불구하고 회사는 갑상선 검사에서 기록적인 성과를 달성했으며, 검사량은 16%, 매출은 전년 대비 25% 증가하여 870만 달러를 기록했습니다.
회사는 2025년 2분기 계속 영업 손실로 50만 달러 손실을 보고했으며, 이는 2024년 2분기 250만 달러 이익과 비교할 때, PancraGEN 검사 중단과 관련된 120만 달러의 일회성 비용이 주된 영향을 미쳤습니다. 현금 수금은 1080만 달러로 견조했으며, 2025년 7월 잠정 매출은 전년 동기 대비 54% 증가한 330만 달러를 기록했습니다.
Interpace는 PancraGEN 환급 손실 이후 갑상선 검사에만 전념하는 방향으로 전환 중이며, 2025년 3분기 이후에도 갑상선 전용 진단 사업으로 긍정적인 전망을 유지하고 있습니다.
Interpace Biosciences (OTCQX:IDXG) a publié des résultats financiers mitigés pour le deuxième trimestre 2025, avec un chiffre d'affaires net de 9,2 millions de dollars, en baisse de 23 % par rapport à l'année précédente. Malgré cette baisse globale des revenus, la société a atteint une performance record dans les tests de la thyroïde, avec un volume en hausse de 16 % et un chiffre d'affaires en hausse de 25 % sur un an, atteignant 8,7 millions de dollars.
La société a enregistré une perte de 0,5 million de dollars provenant des activités poursuivies au deuxième trimestre, contre un bénéfice de 2,5 millions au deuxième trimestre 2024, impactée principalement par des charges exceptionnelles de 1,2 million liées à l'arrêt des tests PancraGEN. Les encaissements sont restés solides à 10,8 millions de dollars, et les revenus préliminaires de juillet 2025 ont montré une augmentation de 54 % sur un an, atteignant 3,3 millions de dollars.
Interpace est en train de se recentrer exclusivement sur les tests thyroïdiens, suite à la perte du remboursement PancraGEN. L'entreprise maintient une perspective positive pour le troisième trimestre 2025 et au-delà en tant qu'activité diagnostique dédiée uniquement à la thyroïde.
Interpace Biosciences (OTCQX:IDXG) meldete gemischte Finanzergebnisse für das zweite Quartal 2025 mit einem Nettoerlös von 9,2 Millionen US-Dollar, was einem Rückgang von 23 % im Jahresvergleich entspricht. Trotz des allgemeinen Umsatzrückgangs erzielte das Unternehmen eine rekordverdächtige Leistung bei Schilddrüsentests, mit einem Volumenanstieg von 16 % und einem Umsatzanstieg von 25 % im Jahresvergleich auf 8,7 Millionen US-Dollar.
Das Unternehmen verzeichnete einen Verlust aus fortgeführten Geschäftstätigkeiten von 0,5 Millionen US-Dollar im zweiten Quartal, verglichen mit einem Gewinn von 2,5 Millionen im zweiten Quartal 2024, was hauptsächlich auf einmalige Belastungen in Höhe von 1,2 Millionen im Zusammenhang mit der Einstellung der PancraGEN-Tests zurückzuführen ist. Die Bareinnahmen blieben mit 10,8 Millionen US-Dollar stark, und die vorläufigen Umsatzzahlen für Juli 2025 zeigten einen Jahresanstieg von 54 % auf 3,3 Millionen US-Dollar.
Interpace befindet sich im Übergang und konzentriert sich ausschließlich auf Schilddrüsentests, nachdem die Erstattung für PancraGEN weggefallen ist. Das Unternehmen blickt optimistisch auf das dritte Quartal 2025 und darüber hinaus als reines Schilddrüsendiagnostik-Unternehmen.
- Record thyroid test volume with 16% year-over-year growth
- Thyroid revenue increased 25% year-over-year to $8.7M
- Strong cash collections of $10.8M in Q2 2025
- Preliminary July 2025 revenue up 54% year-over-year to $3.3M
- Strategic investments in lab operational efficiency and AI automation
- Net revenue decreased 23% year-over-year to $9.2M
- Loss from continuing operations of $0.5M vs $2.5M income in prior year
- Gross profit margin declined to 57% from 65% year-over-year
- Loss of reimbursement for PancraGEN testing
- Cash and cash equivalents declined to $502K from $1.46M at year-end 2024
| ● | Q2 Revenue of | |
| ● | Q2 Cash Collections of | |
| ● | Q2 Thyroid test volume up | |
| ● | Q2 Thyroid revenue of |
PARSIPPANY, NJ, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2025 and provided a business and financial update.
Second quarter Net Revenue was
“Despite the loss of reimbursement for the Company’s PancraGEN test, Q2 2025 represented another quarter of year-over- year double digit Thyroid volume and revenue growth,” stated Tom Burnell, President and CEO. “We are excited about the Company’s continued growth in revenue, profitability and cash flow as a thyroid only clinical diagnostics business, which will be more adequately reflected in Q3 and beyond”, added Burnell. Further, Burnell said, “the strength and resiliency of the Interpace team, coupled with their ability to anticipate and prepare for change, has made for a smooth transition away from the unwarranted challenges as a result of loss of PancraGEN reimbursement to a thriving thyroid testing business”.
Second Quarter 2025 Financial Performance
For the Second Quarter of 2025 as Compared to the Second Quarter of 2024
| ● | Net Revenue was | |
| ● | Gross Profit percentage was | |
| ● | Gross Profit percentage without one-time impact related to PancraGEN reimbursement loss was | |
| ● | Operating loss was | |
| ● | Loss from continuing operations was | |
| ● | Loss from continuing operations includes | |
| ● | Adjusted EBITDA was | |
| ● | Q2 2025 cash collections totaled |
About Interpace Biosciences
Interpace Biosciences is an emerging leader in enabling personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications.
Clinical services, through Interpace Diagnostics, provide clinically useful molecular diagnostic tests and bioinformatics and pathology services for evaluating risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. Interpace has three commercialized molecular tests and one test in a clinical evaluation program (CEP): ThyGeNEXT® for the diagnosis of thyroid cancer from thyroid nodules utilizing a next-generation sequencing assay; ThyraMIR®v2, used in combination with ThyGeNEXT®, for the diagnosis of thyroid cancer utilizing a proprietary microRNA pairwise expression profiler along with algorithmic classification; and RespriDX®, that differentiates lung cancer of primary versus metastatic origin. In addition, BarreGEN®, a molecular-based assay that helps resolve the risk of progression of Barrett’s Esophagus to esophageal cancer, is currently in a CEP, whereby we gather information from physicians using BarreGEN® to assist us in gathering clinical evidence relative to the safety and performance of the test and also providing data that will potentially support payer reimbursement.
For more information, please visit Interpace Biosciences’ website at www.interpace.com.
Forward-looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, relating to the Company’s future financial and operating performance. The Company has attempted to identify forward-looking statements by terminology including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are based on current expectations, assumptions and uncertainties involving judgments about, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the Company’s control. These statements also involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to be materially different from those expressed or implied by any forward-looking statements, including, but not limited to, the possibility that the Company’s estimates of future revenue, cash flows and adjusted EBITDA may prove to be materially inaccurate, the Company’s prior history of operating losses, the Company’s ability to adequately finance its business and seek alternative sources of financing, the Company’s ability to repay borrowings from BroadOak, the Company’s dependence on sales and reimbursements from its clinical services, the Company’s ability to retain or secure reimbursement including its reliance on third parties to process and transmit claims to payers and the adverse impact of any delay, data loss, or other disruption in processing or transmitting such claims, the Company’s revenue recognition being based in part on estimates for future collections which estimates may prove to be incorrect, and the Company’s ability to restructure itself in light of the loss of reimbursement for its PancraGEN product.
Additionally, all forward-looking statements are subject to the “Risk Factors” detailed from time to time in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, as amended, Current Reports on Form 8-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission. Because of these and other risks, uncertainties and assumptions, undue reliance should not be placed on these forward-looking statements. In addition, these statements speak only as of the date of this press release and, except as may be required by law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contacts:
Investor Relations
Interpace Biosciences, Inc.
(855)-776-6419
Info@Interpace.com
INTERPACE BIOSCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited, in thousands, except per share data)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenue, net | $ | 9,232 | $ | 12,042 | $ | 20,747 | $ | 22,219 | ||||||||
| Cost of revenue | 3,956 | 4,236 | 8,101 | 8,102 | ||||||||||||
| Gross Profit | 5,276 | 7,806 | 12,646 | 14,117 | ||||||||||||
| Sales and marketing | 2,910 | 2,887 | 5,723 | 5,707 | ||||||||||||
| Research and development | 173 | 146 | 350 | 283 | ||||||||||||
| General and administrative | 2,661 | 2,141 | 5,211 | 4,381 | ||||||||||||
| Total operating expenses | 5,744 | 5,174 | 11,284 | 10,371 | ||||||||||||
| Operating (loss) income | (468 | ) | 2,632 | 1,362 | 3,746 | |||||||||||
| Interest accretion expense | - | (12 | ) | - | (30 | ) | ||||||||||
| Note payable interest | (49 | ) | (176 | ) | (127 | ) | (373 | ) | ||||||||
| Other (expense) income, net | (16 | ) | 71 | 4 | (12 | ) | ||||||||||
| (Loss) income from continuing operations before tax | (533 | ) | 2,515 | 1,239 | 3,331 | |||||||||||
| Provision for income taxes | - | 4 | 18 | 8 | ||||||||||||
| (Loss) income from continuing operations | (533 | ) | 2,511 | 1,221 | 3,323 | |||||||||||
| Loss from discontinued operations, net of tax | (107 | ) | (74 | ) | (214 | ) | (178 | ) | ||||||||
| Net (loss) income | $ | (640 | ) | $ | 2,437 | $ | 1,007 | $ | 3,145 | |||||||
| Basic income (loss) per share of common stock: | ||||||||||||||||
| From continuing operations | $ | (0.12 | ) | $ | 0.57 | $ | 0.28 | $ | 0.76 | |||||||
| From discontinued operations | (0.02 | ) | (0.02 | ) | (0.05 | ) | (0.04 | ) | ||||||||
| Net income (loss) per basic share of common stock | $ | (0.14 | ) | $ | 0.56 | $ | 0.23 | $ | 0.72 | |||||||
| Diluted income (loss) per share of common stock: | ||||||||||||||||
| From continuing operations | $ | (0.12 | ) | $ | 0.57 | $ | 0.04 | $ | 0.76 | |||||||
| From discontinued operations | (0.02 | ) | (0.02 | ) | (0.01 | ) | (0.04 | ) | ||||||||
| Net income (loss) per diluted share of common stock | $ | (0.14 | ) | $ | 0.55 | $ | 0.04 | $ | 0.72 | |||||||
| Weighted average number of common shares and | ||||||||||||||||
| common share equivalents outstanding: | ||||||||||||||||
| Basic | 4,423 | 4,376 | 4,422 | 4,373 | ||||||||||||
| Diluted | 4,423 | 4,401 | 27,697 | 4,393 | ||||||||||||
Selected Balance Sheet Data (Unaudited)
($ in thousands)
| June 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Cash and cash equivalents | $ | 502 | $ | 1,461 | ||||
| Total current assets | 9,504 | 11,773 | ||||||
| Total current liabilities | 7,149 | 10,615 | ||||||
| Total assets | 12,335 | 14,792 | ||||||
| Total liabilities | 13,548 | 17,009 | ||||||
| Total stockholders' deficit | (1,213 | ) | (2,217 | ) | ||||
Selected Cash Flow Data (Unaudited)
($ in thousands)
| For the Six Months Ended | ||||||||
| June 30, | ||||||||
| 2025 | 2024 | |||||||
| Net income | $ | 1,007 | $ | 3,145 | ||||
| Net cash provided by operating activities | $ | 1,755 | $ | 1,346 | ||||
| Net cash used in investing activities | (201 | ) | (225 | ) | ||||
| Net cash used in financing activities | (2,513 | ) | (2,600 | ) | ||||
| Change in cash and cash equivalents | (959 | ) | (1,479 | ) | ||||
| Cash and cash equivalents – beginning | 1,461 | 3,498 | ||||||
| Cash and cash equivalents – ending | $ | 502 | $ | 2,019 | ||||
Reconciliation of Adjusted EBITDA (Unaudited)
($ in thousands)
| Three Months Ended | Six Months Ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| (Loss) income from continuing operations (GAAP Basis) | $ | (533 | ) | $ | 2,511 | $ | 1,221 | $ | 3,323 | |||||||
| Depreciation and amortization | 101 | 67 | 196 | 119 | ||||||||||||
| Stock-based compensation | 9 | 53 | 24 | 132 | ||||||||||||
| Severance & related expense | 524 | - | 692 | - | ||||||||||||
| Asset impairment - lab supplies | 198 | - | 198 | - | ||||||||||||
| Taxes expense | - | 4 | 18 | 8 | ||||||||||||
| Interest accretion expense | - | 12 | - | 30 | ||||||||||||
| Note payable interest | 49 | 176 | 127 | 373 | ||||||||||||
| Other expense/income, net | 10 | (14 | ) | 14 | (29 | ) | ||||||||||
| Change in fair value of note payable | 7 | (57 | ) | (18 | ) | 41 | ||||||||||
| Adjusted EBITDA | $ | 365 | $ | 2,752 | $ | 2,472 | $ | 3,997 | ||||||||
Non-GAAP Financial Measures
In addition to the United States generally accepted accounting principles, or GAAP, results provided throughout this document, we have provided certain non-GAAP financial measures to help evaluate the results of our performance. We believe that these non-GAAP financial measures, when presented in conjunction with comparable GAAP financial measures, are useful to both management and investors in analyzing our ongoing business and operating performance. We believe that providing the non-GAAP information to investors, in addition to the GAAP presentation, allows investors to view our financial results in the way that management views financial results.
In this document, we discuss Adjusted EBITDA, a non-GAAP financial measure. Adjusted EBITDA is a metric used by management to measure cash flow of the ongoing business. Adjusted EBITDA is defined as income or loss from continuing operations, plus depreciation and amortization, non-cash stock-based compensation, severance expense, interest and taxes, and other non-cash expenses including change in fair values of notes payable. The table above includes a reconciliation of this non-GAAP financial measure to the most directly comparable GAAP financial measure.
FAQ
What were Interpace Biosciences (IDXG) Q2 2025 earnings results?
Why did IDXG's revenue decline in Q2 2025 compared to Q2 2024?
How is IDXG's thyroid testing business performing in 2025?
What is IDXG's financial outlook following Q2 2025 results?
What was IDXG's cash position at the end of Q2 2025?
